Combined RNAi-Mediated Suppression of Rictor and EGFR Resulted in Complete Tumor Regression in an Orthotopic Glioblastoma Tumor Model

• Maite Verreault ,

  * E-mail: maiteverreault@gmail.com (MV); mbally@bccrc.ca (MBB)

  Affiliation Experimental Neurooncology, Brain and Bone Marrow Institute Research Center, Pitie-Salpetriere Hospital, Paris, France

  ⨯
• Sherry A. Weppler,

  Affiliation Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, BC, Canada

  ⨯
• Amelia Stegeman,

  Affiliation Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, BC, Canada

  ⨯
• Corinna Warburton,

  Affiliation Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, BC, Canada

  ⨯
• Dita Strutt,

  Affiliation Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, BC, Canada

  ⨯
• Dana Masin,

  Affiliation Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, BC, Canada

  ⨯
• Marcel B. Bally

  * E-mail: maiteverreault@gmail.com (MV); mbally@bccrc.ca (MBB)

  Affiliations Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, BC, Canada, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver BC, Canada, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada, Center for Drug Research and Development, Vancouver, BC, Canada

  ⨯